Capricor Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: As of June 30, 2026, Capricor reported cash, cash equivalents, and marketable securities totaling $237.9 million.

Revenue: No revenue was recognized for Q2 2026 or Q2 2025.

Operating Expenses: Total operating expenses for Q2 2026 were $42.9 million, up from $27.7 million in Q2 2025, primarily due to investments in clinical, regulatory, and manufacturing activities.

Net Loss: The net loss for Q2 2026 was approximately $40.7 million ($0.70 per share), compared to a net loss of $25.9 million ($0.57 per share) in Q2 2025. For the first half of 2026, the net loss was $74.7 million, compared to $50.3 million for the same period in 2025.

Accumulated Deficit: Approximately $379.6 million as of June 30, 2026.

2Strategic Updates and Business Highlights

Regulatory Status: The Biologics License Application (BLA) for Daramycin is under review by the FDA, with a PDUFA target action date of August 22, 2026. The FDA advisory committee voted 3 in favor and 9 against the effectiveness of Daramycin for treating cardiomyopathy in DMD patients.

Path Forward: Capricor plans to submit an amendment to the BLA focusing on an upper limb skeletal muscle indication, which aligns with the primary efficacy endpoint of the HOPE-3 study.

Publication: Results from the HOPE-3 clinical trial were published in The Lancet, highlighting the efficacy of Daramycin.

Commercial Readiness: The company is progressing with commercial readiness activities, albeit at a slower pace pending regulatory clarity. The in-house GMP manufacturing facility is operational and supports initial commercial launch plans.

3Forward Guidance and Outlook

Capricor aims to submit updated data to the FDA as soon as possible and anticipates an extension of the PDUFA action date following the amendment submission.

The company is focusing on lifecycle management for Daramycin, including regulatory engagement in Europe and Japan, while other pipeline activities are on hold until further regulatory clarity is achieved.

4Bad News, Challenges, or Points of Concern

Advisory Committee Vote: The unfavorable vote (3 in favor, 9 against) from the FDA advisory committee regarding Daramycin's effectiveness for cardiomyopathy was a significant setback.

Regulatory Challenges: The ongoing dispute with NS Pharma regarding the U.S. distribution agreement could impact patient access and commercialization efforts.

Increased Losses: The rising net losses and operating expenses indicate financial strain as the company invests heavily in regulatory and commercial activities without immediate revenue.

5Notable Q&A Insights

There was no Q&A session during this earnings call due to the sensitivity of ongoing discussions with the FDA. The management expressed a commitment to provide updates as they become available. Overall, while Capricor Therapeutics is making strides in its regulatory and commercial efforts for Daramycin, it faces significant challenges, particularly regarding the recent advisory committee vote and ongoing disputes that could affect its path forward.